Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Tanios Bekaii-Saab
Ohio State University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- Emory University
Atlanta, Georgia, United States
- University of Michigan Cancer Center (umcc) Research Base
Ann Arbor, Michigan, United States
- Wayne State University
Detroit, Michigan, United States
- University of North Carolina
Chapel Hill, North Carolina, United States
- Ohio State University Medical Center
Columbus, Ohio, United States
- Vanderbilt University
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2007
- Primary completion
- 31 Jan 2013
- Completion
- 31 Jan 2013
- Last update posted
- 22 Apr 2016
- Registered enrollment
- 29
- Registry id
- NCT00553332
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.